Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Matthew D. Galsky, Sergio Bracarda et al.|The Lancet Oncology|2017Cited by 1.8k
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyJesús García-Donás, Cristina Rodríguez‐Antona, Emilio Esteban et al.|The Lancet Oncology|2011Cited by 221
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinomaJesús García-Donás, Cristina Rodríguez‐Antona, Luis J. Leandro‐García et al.|Annals of Oncology|2013Cited by 74
Deep sequencing reveals microRNAs predictive of antiangiogenic drug responseJesús García-Donás, Cristina Rodríguez‐Antona, Benoit Beuselinck et al.|JCI Insight|2016Cited by 48
PTEN expression and mutations in <i>TSC1</i>, <i>TSC2</i> and <i>MTOR</i> are associated with response to rapalogs in patients with renal cell carcinomaJuan María Roldán‐Romero, Benoit Beuselinck, María Santos et al.|International Journal of Cancer|2019Cited by 29